Patent: 9,295,669
✉ Email this page to a colleague
Summary for Patent: 9,295,669
Title: | Combination therapy for proliferative disorders |
Abstract: | The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difl- uoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation. |
Inventor(s): | Dhingra; Kapil (Sparta, NJ), Higgins; Brian (Fresh Meadows, NY), Kolinsky; Kenneth (Bloomingdale, NJ), Lee; Richard J. (New York, NY), Lestini; Brian (Union City, NJ), Packman; Kathryn (Bloomfield, NJ), Su; Fei (Paramus, NJ) |
Assignee: | Hoffman La-Roche Inc. (Nutley, NJ) |
Application Number: | 13/313,042 |
Patent Claims: | see list of patent claims |
Details for Patent 9,295,669
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Zr Pharma& Gmbh | PEGASYS | peginterferon alfa-2a | Injection | 103964 | 10/16/2002 | ⤷ Try a Trial | 2030-12-14 |
Zr Pharma& Gmbh | PEGASYS | peginterferon alfa-2a | Injection | 103964 | 01/07/2004 | ⤷ Try a Trial | 2030-12-14 |
Zr Pharma& Gmbh | PEGASYS | peginterferon alfa-2a | Injection | 103964 | 09/29/2011 | ⤷ Try a Trial | 2030-12-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |